SCHEMBL11920163

SCHEMBL11920163

N#Cc1ccc(-c2nnc(CCl)o2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
LMNA P02545 2/20 0.64
NOTUM Q6P988 5/20 0.57
NPC1 O15118 3/20 0.51
MAPT P10636 2/20 0.51
PKM P14618 1/20 0.51
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
GSK3B P49841 5/20 0.49
POLB P06746 2/20 0.46
TSHR P16473 2/20 0.46
USP2 O75604 1/20 0.46
GSK3A P49840 2/20 0.45
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
TNKS O95271 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17001607 0.83 MAPT (0.51) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL27864374 0.81 MAOA (0.68) ALDH1A1NOTUMNPC1MAPTPKM
SCHEMBL1544399 0.81 ALDH1A1 (0.61) ALDH1A1LMNANOTUMNPC1GSK3B
SCHEMBL2640766 0.80 ALDH1A1 (0.70) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL25916050 0.79 ALDH1A1 (0.68) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL2640701 0.79 ALDH1A1 (0.68) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL5124689 0.79 ALDH1A1 (0.68) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL5117429 0.79 ALDH1A1 (0.68) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL3423891 0.79 TSHR (0.73) ALDH1A1LMNANOTUMNPC1MAPT
SCHEMBL485159 0.78 ALDH1A1 (1.00) ALDH1A1LMNANOTUMNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 ALDH1A1 1296/4885LMNA 1015/4885NOTUM 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.